All News

Megan Olsen, MPH, principal at Avalere, explains how payers are attempting to get around cost concerns associated with expensive cell and gene therapies.

This new analysis of more than 11 million veterans investigated risks of several cardiovascular diseases beyond the first 30 days after COVID-19 infection.

A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field.

The CDC laid out a plan for mass rollout of COVID-19 vaccines for children under 5 years old, pending FDA authorization; President Biden pivots focus onto drug pricing to revive his social spending agenda; Teva opioid settlements could total $3.6 billion when all’s said and done.

Researchers reviewed advances in the management of chronic rhinosinusitis, with and without nasal polyps, from 2020 to 2021.

The researchers said they did the study with the aim of finding more information about the interaction between age and Parkinson disease (PD) in an effort to improve patient management and therapy development.

Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.

A new report from the Republic of Korea compared outcomes among women following neoadjuvant chemotherapy and mastectomy who did or did not receive radiotherapy.

A small proportion of patients have symptoms of both asthma and chronic obstructive pulmonary disease. A new report suggests there might be an intermediate phenotype.

Researchers concluded that incident corneal adverse events in patients with multiple myeloma (MM) carry a low clinical and economic burden compared with total all-cause costs and MM-related per-patient-per-month costs.

Worldwide COVID-19 cases drop by 17%, with deaths decreasing by 7%; Johnson & Johnson temporarily stopped COVID-19 vaccine production in the Netherlands; Amazon begins nationwide rollout of its telehealth service, Amazon Care.

Version 5 of “COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases" includes updated recommendations that differentiate supplemental and booster doses for people with rheumatic and musculoskeletal diseases (RMDs).

Arizona introduced revisions to a bill that provides protections for patients with chronic intractable pain, which passed unanimously from the Senate Health Committee to the full Senate and will go the House Health Committee for vote in the coming weeks.

Using data from a meta-analysis, researchers determined tumor-stroma ratio could serve as a survival predictor in non–small cell lung cancer (NSCLC).

Patients with chronic rhinosinusitis with nasal polyps who had elevated serum amyloid A (SAA) levels were more likely to achieve disease-controlled status vs those with low SAA levels after endoscopic sinus surgery.

Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.

Data from SURPASS-5 show Eli Lilly's glucagon-like peptide-1 receptor agonist tirzepatide helped improve glycemic control when taken with insulin glargine.

Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, discusses delayed booster vaccines and potential fourth doses for people who are immunosuppressed.

Patients with multiple myeloma (MM) who have been fully vaccinated against COVID-19 were found to have an increased risk of breakthrough infections and related hospitalizations, signaling the need for more studies and precautions.

Serum levels of 4 key cytokines were decreased after 8 weeks of mild exercise, compared with controls.

A bipartisan congressional report estimates overdose deaths cost the United States $1 trillion yearly; 4 states announce plans to lift their statewide mask mandates for schools; study finds greater risk of pregnancy complications in expectant mothers with moderate COVID-19 symptoms.

Findings of the largest genome-wide association study conducted among migraineurs to date revealed novel risk factors for the condition, stratified by aura presence.

Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.

Patients with chronic kidney disease (CKD) and their caregivers who have participated in CKD research shared factors that may encourage or discourage others from enrolling in clinical studies, highlighting the ways that investigators can better involve patients in research.

A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.

The drug will be marketed by Sanofi under the name Enjaymo; it is the first treatment approved for cold agglutinin disease.

Poor agreement was identified regarding MRI- and classification-defined axial spondyloarthritis (axSpA) and inflammatory back pain diagnoses in patients with psoriatic disease.

Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, explains the background and results of the TOPAZ-1 study.

The CDC's wastewater monitoring program will soon begin evaluating more water samples for COVID-19; vaccine guidance changes for individuals who are immunocompromised may be forthcoming; exposure to air pollution levels vastly greater than that advised by World Health Organization guidelines.